Overview

Liposome Bupivacaine Interscalene Total Shoulder

Status:
Recruiting
Trial end date:
2020-12-01
Target enrollment:
0
Participant gender:
All
Summary
This is a randomized prospective outcomes study comparing two groups of patients. One group will receive liposomal bupivacaine plus bupivacaine and the other will receive bupivacaine alone in interscalene blocks when undergoing total shoulder arthroplasty. The purpose of the study is to determine if LB plus bupivacaine provides superior pain control compared to bupivacaine alone when injected in an interscalene block for patients undergoing total shoulder arthroplasty surgery.
Phase:
Phase 2
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
University of Minnesota
University of Minnesota - Clinical and Translational Science Institute
Treatments:
Bupivacaine
Criteria
Inclusion Criteria:

- All adult patients aged greater than 18 years of age that are undergoing total or
reverse total shoulder arthroplasty

Exclusion Criteria:

- Patients with allergy to local anesthetics, daily use of opioids for more than 3 weeks
prior to surgery, patient refusal, patient with coagulopathy, non-english speaking
patients, and those who do not have access to a telephone.